Affimed N.V. (AFMD)
Market Cap | 78.50M |
Revenue (ttm) | 4.26M |
Net Income (ttm) | -101.23M |
Shares Out | 15.23M |
EPS (ttm) | -6.73 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 144,177 |
Open | 5.38 |
Previous Close | 5.41 |
Day's Range | 5.07 - 5.46 |
52-Week Range | 2.24 - 8.95 |
Beta | 2.04 |
Analysts | Strong Buy |
Price Target | 30.83 (+498.06%) |
Earnings Date | Jun 12, 2024 |
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatme... [Read more]
Financial Performance
In 2023, Affimed's revenue was 8.28 million, a decrease of -79.99% compared to the previous year's 41.35 million. Losses were -105.94 million, 23.2% more than in 2022.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AFMD stock is "Strong Buy." The 12-month stock price forecast is $30.83, which is an increase of 498.06% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/t/t/press19-2475073.jpg)
Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) -
![](https://cdn.snapi.dev/images/v1/o/m/conf5-2463129.jpg)
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
![](https://cdn.snapi.dev/images/v1/z/h/press19-2457731.jpg)
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
MANNHEIM, Germany, June 01, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today...
![](https://cdn.snapi.dev/images/v1/5/n/press14-2451084.jpg)
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic...
![](https://cdn.snapi.dev/images/v1/q/m/press9-2449355.jpg)
Affimed Announces Annual General Meeting of Shareholders
MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/t/v/press3-2446522.jpg)
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
MANNHEIM, Germany, May 23, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today ...
![](https://cdn.snapi.dev/images/v1/w/a/press12-2429692.jpg)
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today ...
![](https://cdn.snapi.dev/images/v1/k/u/press10-2387332.jpg)
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...
![](https://cdn.snapi.dev/images/v1/s/i/press4-2345648.jpg)
Affimed Reports 2023 Financial Results and Operational Progress
MANNHEIM, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
![](https://cdn.snapi.dev/images/v1/e/p/conf10-2334764.jpg)
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
![](https://cdn.snapi.dev/images/v1/w/c/press19-2310377.jpg)
Affimed Announces 1-for-10 Reverse Stock Split
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
![](https://cdn.snapi.dev/images/v1/v/i/press12-2221113.jpg)
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/i/i/press1-2220042.jpg)
Affimed Announces Leadership Change and Organizational Restructuring
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
![](https://cdn.snapi.dev/images/v1/w/p/press10-2214254.jpg)
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/y/o/press1-2190650.jpg)
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/9/0/press11-2190643.jpg)
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
MANNHEIM, Germany, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/p/p/conf1-2181450.jpg)
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
![](https://cdn.snapi.dev/images/v1/e/s/press3-2156300.jpg)
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
MANNHEIM, Germany, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/0/b/press5-2149193.jpg)
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/i/9/conf18-2143396.jpg)
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, annou...
![](https://cdn.snapi.dev/images/v1/d/f/press1-2139482.jpg)
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
MANNHEIM, Germany, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
![](https://cdn.snapi.dev/images/v1/y/w/press3-2136188.jpg)
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
MANNHEIM, Germany, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
![](https://cdn.snapi.dev/images/v1/b/y/conf17-2132274.jpg)
Affimed to Participate in Upcoming Investor Conferences
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
![](https://cdn.snapi.dev/images/v1/h/4/press2-2088986.jpg)
Affimed Announces Listing Transfer to Nasdaq Capital Markets
MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
![](https://cdn.snapi.dev/images/v1/y/u/press11-2079802.jpg)
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...